Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03064906 · ClinicalTrials.gov registry record · NA
Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT03064906: Completed NA study, sponsored by Insulet Corporation.
NCT03064906 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03064906, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type 1 diabetes consuming high fat meals and undertaking moderate intensity exercise.
Interventions
- DEVICE Insulet AP (artificial pancreas) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-03-18 |
| Est. Completion | 2017-04-07 |
| Phase | NA |
What the finished NCT03064906 record still lists
NCT03064906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Insulet AP (artificial pancreas) System is the first listed.
NCT03064906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03064906 about?
NCT03064906 is a clinical study titled "Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)". To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type 1 diabetes consuming high fat meals and undertaking moderate intensity...
What is the current status of trial NCT03064906?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-03-18. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT03064906?
The interventions under investigation include: Insulet AP (artificial pancreas) System (DEVICE).
Who is sponsoring clinical trial NCT03064906?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03064906's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI